（编辑 丛可心） 证券日报网讯 2月10日，红日药业在互动平台回答投资者提问时表示，公司已在全国范围内布局北京、 天津、河北、湖北、河南、重庆、甘肃、山东8大生产基地，并建立了从药材、饮片、提取、制剂、包 装、销售的全过程追溯体系，实现了配方颗粒全品种溯源。 ...

Group 1 - The JPM 2026 conference revealed innovative opportunities in the pharmaceutical and medical device sectors, particularly in the IO plus field where the trend of using VEGF dual antibodies in multiple indications is becoming established [1] - There is a focus on multinational corporations (MNCs) and leading biotech companies developing dual antibodies and combinations with monoclonal antibodies targeting other immune-related sites [1] - In the ADC (Antibody-Drug Conjugate) area, attention is drawn to first-in-class (FIC) products for large indications, new indications for major products, and advancements in dual toxin/new toxin ADC technologies, which are leading directions for domestic innovative drugs [1] Group 2 - The ETF Guotai (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [2] - The index emphasizes the R&D investment and technological leadership of constituent companies, focusing on high-growth potential in the pharmaceutical health sector [2] - The ETF aims to reflect the overall performance of listed companies related to innovative biopharmaceuticals [2]

Group 1 - The company is steadily advancing its research and development, as well as production technology innovation [1] - The goal of the company is to become a leader in the new era of traditional Chinese medicine industry [1]

Group 1 - The company, Hongri Pharmaceutical, is actively conducting research on classic prescriptions and new traditional Chinese medicine drugs in accordance with the requirements of the National Medical Products Administration [1]

Group 1 - The company Huaren Pharmaceutical (03320) announced that its non-wholly owned subsidiary Dong'e Ejiao (000423.SZ) has decided to invest in and construct a health consumer goods industrial park [1] - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing and logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1] - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, including production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1] Group 2 - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine and establish a dual-driven business growth model of pharmaceuticals and health consumer goods [2] - The existing industrial park of Dong'e Ejiao faces limitations in expansion area and capacity bottlenecks in major production lines, which cannot meet the rapid upgrading and iteration needs of health consumer products [2] - Building the new facilities will help Dong'e Ejiao establish a core advantage in the health consumer goods sector, with a focus on Ejiao series products, enhancing brand regional recognition, and strengthening core competitiveness [2]

Core Viewpoint - Yunnan Baiyao Group Co., Ltd. aims to enhance its modern R&D system and capabilities by integrating traditional Chinese medicine with modern technology, thereby injecting strategic momentum for sustainable long-term development [1] Group 1 - The company has appointed Zhu Zhaoyun as the Traditional Chinese Medicine Strategic Scientist and Zhang Ning as the Chief Scientist to support its strategic goals [1]

九芝堂公告称，持股5%以上股东、副董事长兼总经理李振国，于2026年2月9日通过大宗交易减持公司 股份862万股，占公司剔除回购专用账户股份后总股本的1.02%。减持后，其持股数量从16189.8371万股 降至15327.8371万股，持股比例从19.13%降至18.11%。此次减持是履行前期计划，目前减持计划尚未实 施完毕。 ...

Group 1 - The core point of the article is that Qizheng Tibetan Medicine has successfully registered its classic Tibetan medicine, Cuotang Granules, in Macau, marking a significant step in the company's internationalization strategy [2][3] - Cuotang Granules is the first Tibetan medicine approved in the Macau Special Administrative Region, indicating a breakthrough for the company in expanding its market presence [2][3] - The product is classified as an over-the-counter (OTC) traditional Chinese medicine, allowing it to be sold directly to consumers through retail pharmacies in Macau [2] Group 2 - The approval of Cuotang Granules aligns with the development of Macau as a key area for traditional Chinese medicine and its international outreach, contributing to the broader strategy of the Guangdong-Hong Kong-Macau Greater Bay Area [3] - This registration is part of a series of achievements in the respiratory field for Qizheng Tibetan Medicine, following the approval of Shiwai Longdan Huagao Capsules as a protected traditional Chinese medicine variety [4] - The company aims to leverage the combination of classic Tibetan medicine, Hong Kong-Macau standards, and international distribution to create a replicable model for ethnic medicine going global [3]

Core Viewpoint - The company, Buchang Pharma, emphasizes steady operations and innovative development while maintaining a strong commitment to shareholder returns and social responsibility, showcasing a clear blueprint for high-quality growth [1][2][4][5]. Shareholder Returns - Buchang Pharma has established a dual return mechanism of "dividends + buybacks," with cumulative dividends reaching 7.948 billion yuan and share buybacks totaling 1.744 billion yuan, significantly exceeding the IPO fundraising amount of 3.9 billion yuan [2]. - In 2022, the company distributed cash dividends of 1.062 billion yuan and completed share buybacks worth 934 million yuan, while in 2025, it increased buybacks by acquiring 6.6206 million shares for nearly 100 million yuan [2]. - The first buyback plan in 2026 involved repurchasing 2.176 million shares at a price significantly lower than the upper limit, demonstrating efficient capital management [2]. Social Responsibility - Buchang Pharma integrates social responsibility into its corporate DNA, supporting the "Together, Build a Chinese Heart" public welfare initiative, which has organized 32,000 volunteers and provided free surgeries for over 3,800 children with congenital heart disease [3]. - The company has contributed nearly 33 billion yuan in taxes since its establishment, playing a vital role in local economic development and rural revitalization [3]. Business Fundamentals - The company has a strong business foundation, focusing on major diseases like cardiovascular issues, with over 170 products included in the 2025 National Medical Insurance Directory [4]. - Buchang Pharma is expanding into biopharmaceuticals and chemical drugs, with its first Class 1 new drug expected to fill a market gap, and multiple innovative cancer drugs in critical clinical stages [4]. International Strategy - The company is deepening its international strategy through "product registration + international cooperation," successfully registering several products in countries like Malaysia and Canada [5]. - Buchang Pharma's products are now sold in dozens of countries, and strategic partnerships with companies in Malaysia and Russia are enhancing its global market penetration [5].

每经AI快讯，有投资者在投资者互动平台提问：请问贵公司同哪些中医药高等院校有研发合作？ （记者 王晓波） 红日药业（300026.SZ）2月10日在投资者互动平台表示，公司目前与北京中医药大学、天津中医药大 学、成都中医药大学、安徽中医药大学等院校有合作。 ...